Treatment of hepatorenal syndrome octreotide vs. midodrine vs. norepinephrine as part of triple therapy / Osman Mohamed Osman ; Supervised Fahim Ragab , Mohamed Elshafie , Ayman Moharram
Material type: TextLanguage: English Publication details: Cairo : Osman Mohamed Osman , 2012Description: 85Leaves : charts ; 30cmOther title:- علاج متلازمة الفشل الكبدى الكلوى مقارنة بين أوكتريوتايد : ميدودرين ونوابينفرين كجزء من العلاج الثلاثى [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
Thesis | قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.09.M.Sc.2012.Os.T (Browse shelf(Opens below)) | Not for loan | 01010110058925000 | |||
CD - Rom | مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.09.M.Sc.2012.Os.T (Browse shelf(Opens below)) | 58925.CD | Not for loan | 01020110058925000 |
Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Critical Care Medicine
Hepatorenal syndrome is a serious complication of liver cirrhosis . Splanchnic vasodilatation is the main pathology . Vasoconstrictors are used as treatment aiming at reversal of renal dysfunction . Thirty patients with hepatorenal syndrome were randomized into three groups each receiving albumin , dopamine (nephrogenic dose) and vasoconstrictor (norepinephrine , midodrine or octreotide)
Issued also as CD
There are no comments on this title.